Top Story

NY Presbyterian appoints director of experimental therapeutics

February 1, 2015

Richard D. Carvajal, MD, has been named director of the experimental therapeutics/phase 1 program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center.

Carvajal previously served as director of developmental therapeutics and chair for junior faculty at Memorial Sloan Kettering Cancer Center.

FDA NewsDrug Pipeline

FDA grants orphan drug status to SL-701 for glioma treatment

January 30, 2015
The FDA today granted orphan drug designation to SL-701 for the treatment of glioma, according to a press release from the drug’s manufacturer.SL-701 (Stemline…
Mary Ann Burg, PhD, LCSW In the JournalsPerspective

Cancer survivors' needs 'not sufficiently addressed' by medical community

January 30, 2015
Physical, financial, emotional and mental health problems persist as unmet needs in cancer survivors, according to study results. Mary Ann Burg, PhD, LCSW, professor…
In the Journals

Molecular subtypes of stage III colon cancer linked to different patient outcomes

January 30, 2015
Researchers have identified subtypes of stage III colon cancer based on molecular markers associated with differences in clinical and pathological features as well as…
Lecia V. Sequist, MD, MPH In the Journals

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

January 30, 2015
Patients with lung adenocarcinoma who harbored exon 19 deletion EGFR mutations experienced significantly longer OS when treated with first-line afatinib instead of…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan